| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 Jan 2026 | 13 Jan 2026 |
| Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (the Company) is scheduled to be held on Wednesday January 21 2026 to consider and approve inter-alia the Unaudited Financial Results of the company for the quarter and nine months ended December 31 2025 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2025. Pursuant to Regulation 33 of SEBI (LODR) 2015, we would like to inform you that the board of directors at its meeting held today, inter-alia, considered and approved the unaudited financial results for the quarter and nine months ended December 31, 2025 (As Per BSE Announcement Dated on:21.01.2026) | ||
| Board Meeting | 3 Nov 2025 | 27 Oct 2025 |
| Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (LODR) 2015 it is inform you that meeting of the board of directors is scheduled be held on November 03 2025 to consider the unaudited Financial results of Company for the quarter ended September 30 2025. Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Financial Results for the quarter and half year ended September 30, 2025. kindly find enclosed the Unaudited Financial Results along with its Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2025 Pursuant to regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015 Please find enclosed the Unaudited Financial results along with its Limited review report of the Company for the quarter and half year ended September 30, 2025. (As Per Bse Announcement dated on 03/11/2025) | ||
| Board Meeting | 26 Jul 2025 | 23 Jul 2025 |
| Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2025 inter alia to consider and approve Un- Audited Financial Results for the quarter ended June 30 2025 Outcome of Board Meeting Held on July 26, 2025 along with the Unaudited Financial Results for the quarter ended June 30, 2025. Unaudited Financial results for the quarter ended June 30, 2025 (As Per BSE Announcement Dated on :26.07.2025) | ||
| Board Meeting | 6 May 2025 | 29 Apr 2025 |
| Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2025 inter alia to consider and approve Financial results for the quarter and year ended March 31 2025 and recommendation of Dividend if any for the financial year ended March 31 2025 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the following: 1. Audited (Standalone) Financial Results along with Independent Auditors Review Report issued by the Statutory Auditors of the Company for the quarter and year ended March 31, 2025. 2. The Board recommended a dividend of Rs. 2.5/- (125%) per equity share having face value of Rs. 2 for the financial year ended March 31, 2025. 3. Appointment of M/s. S S Kothari Mehta & Co., Chartered Accountants as Internal Auditor of the Company for FY 2025-26. The Board Meeting commenced at 5:10 p.m. and concluded at 5:46 p.m (As per BSE Announcement Dated on 06/05/2025) | ||
| Board Meeting | 13 Mar 2025 | 13 Mar 2025 |
| Appointment of Mr. Pratham Rawal as Company Secretary and Compliance Officer of the Company w.e.f. March 13, 2025 | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
